President and CEO of Regenxbio Inc (30-Year Financial, Insider Trades) Kenneth T. Mills (insider trades) sold 15,000 shares of RGNX on 07/19/2019 at an average price of $49.49 a share. The total sale was $742,350.
Regenxbio Inc is a biotechnology company. It is engaged in the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Regenxbio Inc has a market cap of $1.8 billion; its shares were traded at around $49.06 with and P/S ratio of 20.69. GuruFocus has detected 4 severe warning signs with Regenxbio Inc. .
CEO Recent Trades:
- President and CEO Kenneth T. Mills sold 15,000 shares of RGNX stock on 07/19/2019 at the average price of $49.49. The price of the stock has decreased by 0.87% since.
Directors and Officers Recent Trades:
- SVP, General Counsel Patrick J. Christmas sold 5,000 shares of RGNX stock on 07/19/2019 at the average price of $50.03. The price of the stock has decreased by 1.94% since.
For the complete insider trading history of RGNX, click here
.